Benzimidazole- and benzoxazole-based inhibitors of Rho kinase

E. Hampton Sessions, Yan Yin, Thomas D. Bannister, Amiee Weiser, Evelyn Griffin, Jennifer Pocas, Michael D. Cameron, Claudia Ruiz, Li Lin, Stephan C Schuerer, Thomas Schröter, Philip LoGrasso, Yangbo Feng

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Inhibitors of Rho kinase have been developed based on two distinct scaffolds, benzimidazoles, and benzoxazoles. SAR studies and efforts to optimize the initial lead compounds are described. Novel selective inhibitors of ROCK-II with excellent potency in both enzyme and cell-based assays were obtained. These inhibitors possess good microsomal stability, low cytochrome P-450 inhibitions and good oral bioavailability.

Original languageEnglish
Pages (from-to)6390-6393
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume18
Issue number24
DOIs
StatePublished - Dec 15 2008
Externally publishedYes

Fingerprint

Benzoxazoles
Benzimidazoles
Lead compounds
rho-Associated Kinases
Scaffolds
Cytochrome P-450 Enzyme System
Biological Availability
Assays
Enzymes
benzimidazole
Lead

Keywords

  • Aminopyrimidine
  • Benzimidazole
  • Benzoxazole
  • Chroman
  • Glaucoma
  • Hypertension
  • Pyrazole
  • Rho kinase
  • Rock-II

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Sessions, E. H., Yin, Y., Bannister, T. D., Weiser, A., Griffin, E., Pocas, J., ... Feng, Y. (2008). Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. Bioorganic and Medicinal Chemistry Letters, 18(24), 6390-6393. https://doi.org/10.1016/j.bmcl.2008.10.095

Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. / Sessions, E. Hampton; Yin, Yan; Bannister, Thomas D.; Weiser, Amiee; Griffin, Evelyn; Pocas, Jennifer; Cameron, Michael D.; Ruiz, Claudia; Lin, Li; Schuerer, Stephan C; Schröter, Thomas; LoGrasso, Philip; Feng, Yangbo.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 18, No. 24, 15.12.2008, p. 6390-6393.

Research output: Contribution to journalArticle

Sessions, EH, Yin, Y, Bannister, TD, Weiser, A, Griffin, E, Pocas, J, Cameron, MD, Ruiz, C, Lin, L, Schuerer, SC, Schröter, T, LoGrasso, P & Feng, Y 2008, 'Benzimidazole- and benzoxazole-based inhibitors of Rho kinase', Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 24, pp. 6390-6393. https://doi.org/10.1016/j.bmcl.2008.10.095
Sessions EH, Yin Y, Bannister TD, Weiser A, Griffin E, Pocas J et al. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. Bioorganic and Medicinal Chemistry Letters. 2008 Dec 15;18(24):6390-6393. https://doi.org/10.1016/j.bmcl.2008.10.095
Sessions, E. Hampton ; Yin, Yan ; Bannister, Thomas D. ; Weiser, Amiee ; Griffin, Evelyn ; Pocas, Jennifer ; Cameron, Michael D. ; Ruiz, Claudia ; Lin, Li ; Schuerer, Stephan C ; Schröter, Thomas ; LoGrasso, Philip ; Feng, Yangbo. / Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. In: Bioorganic and Medicinal Chemistry Letters. 2008 ; Vol. 18, No. 24. pp. 6390-6393.
@article{43b672b34edb458c9e570c43f58dce01,
title = "Benzimidazole- and benzoxazole-based inhibitors of Rho kinase",
abstract = "Inhibitors of Rho kinase have been developed based on two distinct scaffolds, benzimidazoles, and benzoxazoles. SAR studies and efforts to optimize the initial lead compounds are described. Novel selective inhibitors of ROCK-II with excellent potency in both enzyme and cell-based assays were obtained. These inhibitors possess good microsomal stability, low cytochrome P-450 inhibitions and good oral bioavailability.",
keywords = "Aminopyrimidine, Benzimidazole, Benzoxazole, Chroman, Glaucoma, Hypertension, Pyrazole, Rho kinase, Rock-II",
author = "Sessions, {E. Hampton} and Yan Yin and Bannister, {Thomas D.} and Amiee Weiser and Evelyn Griffin and Jennifer Pocas and Cameron, {Michael D.} and Claudia Ruiz and Li Lin and Schuerer, {Stephan C} and Thomas Schr{\"o}ter and Philip LoGrasso and Yangbo Feng",
year = "2008",
month = "12",
day = "15",
doi = "10.1016/j.bmcl.2008.10.095",
language = "English",
volume = "18",
pages = "6390--6393",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "24",

}

TY - JOUR

T1 - Benzimidazole- and benzoxazole-based inhibitors of Rho kinase

AU - Sessions, E. Hampton

AU - Yin, Yan

AU - Bannister, Thomas D.

AU - Weiser, Amiee

AU - Griffin, Evelyn

AU - Pocas, Jennifer

AU - Cameron, Michael D.

AU - Ruiz, Claudia

AU - Lin, Li

AU - Schuerer, Stephan C

AU - Schröter, Thomas

AU - LoGrasso, Philip

AU - Feng, Yangbo

PY - 2008/12/15

Y1 - 2008/12/15

N2 - Inhibitors of Rho kinase have been developed based on two distinct scaffolds, benzimidazoles, and benzoxazoles. SAR studies and efforts to optimize the initial lead compounds are described. Novel selective inhibitors of ROCK-II with excellent potency in both enzyme and cell-based assays were obtained. These inhibitors possess good microsomal stability, low cytochrome P-450 inhibitions and good oral bioavailability.

AB - Inhibitors of Rho kinase have been developed based on two distinct scaffolds, benzimidazoles, and benzoxazoles. SAR studies and efforts to optimize the initial lead compounds are described. Novel selective inhibitors of ROCK-II with excellent potency in both enzyme and cell-based assays were obtained. These inhibitors possess good microsomal stability, low cytochrome P-450 inhibitions and good oral bioavailability.

KW - Aminopyrimidine

KW - Benzimidazole

KW - Benzoxazole

KW - Chroman

KW - Glaucoma

KW - Hypertension

KW - Pyrazole

KW - Rho kinase

KW - Rock-II

UR - http://www.scopus.com/inward/record.url?scp=56249124570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56249124570&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2008.10.095

DO - 10.1016/j.bmcl.2008.10.095

M3 - Article

C2 - 18996009

AN - SCOPUS:56249124570

VL - 18

SP - 6390

EP - 6393

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 24

ER -